Suppr超能文献

奥密克戎变异株感染个体的恢复期血清中不存在针对原始 SARS-CoV-2 病毒或其伽马变异株的中和抗体。

Absence of neutralizing antibodies against the Omicron SARS-CoV-2 variant in convalescent sera from individuals infected with the ancestral SARS-CoV-2 virus or its Gamma variant.

机构信息

Instituto de Medicina Tropical de Sao Paulo, Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, SP, Brazil; Departamento de Moléstias Infecciosas e Parasitarias da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.

Instituto de Medicina Tropical de Sao Paulo, Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, SP, Brazil; Faculdade de Medicina da Universidade Municipal de Sao Caetano do Sul, São Caetano, SP, Brazil.

出版信息

Clinics (Sao Paulo). 2022 Jun 16;77:100068. doi: 10.1016/j.clinsp.2022.100068. eCollection 2022.

Abstract

OBJECTIVES

The aim of the present study was to evaluate if neutralizing antibody responses induced by infection with the SARS-CoV-2 strain that was dominant at the beginning of the pandemic or by the Gamma variant was effective against the Omicron variant.

METHODS

Convalescent sera from 109 individuals, never exposed to a SARS-CoV-2 vaccine, who had mild or moderate symptoms not requiring hospitalization following either a documented SARS-CoV-2 ancestral strain infection or a Gamma variant infection, were assayed for in vitro neutralizing antibody activity against their original strains and the Omicron variant.

RESULTS

Following an infection with the ancestral strain, 56 (93.3%), 45 (77.6%) and 1 (1.7%) serum sample were positive for neutralizing antibodies against the ancestral, Gamma variant, and Omicron variant, respectively. After infection with the Gamma variant, 43 (87.8%) and 2 (4.1%) sera were positive for neutralizing antibodies against the Gamma and Omicron variants, respectively.

CONCLUSIONS

Neutralizing antibodies generated following mild or moderate infection with the SARS-CoV-2 ancestral strain or the Gamma variant are not protective against the Omicron variant.

摘要

目的

本研究旨在评估感染大流行初期占主导地位的 SARS-CoV-2 株或 Gamma 变异株诱导的中和抗体反应是否对奥密克戎变异株有效。

方法

对从未接种过 SARS-CoV-2 疫苗、因感染 SARS-CoV-2 原始株或 Gamma 变异株而出现无需住院治疗的轻症或中度症状的 109 名个体的恢复期血清进行体外中和抗体活性检测,以评估其对原始株和奥密克戎变异株的中和抗体活性。

结果

感染原始株后,分别有 56 份(93.3%)、45 份(77.6%)和 1 份(1.7%)血清样本对原始株、Gamma 变异株和奥密克戎变异株的中和抗体呈阳性。感染 Gamma 变异株后,分别有 43 份(87.8%)和 2 份(4.1%)血清样本对 Gamma 和奥密克戎变异株的中和抗体呈阳性。

结论

感染 SARS-CoV-2 原始株或 Gamma 变异株引起的轻症或中度感染产生的中和抗体不能预防奥密克戎变异株。

相似文献

7
Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection.
Emerg Microbes Infect. 2022 Dec;11(1):1828-1832. doi: 10.1080/22221751.2022.2099305.
10
Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron.
Cell Rep. 2022 May 24;39(8):110862. doi: 10.1016/j.celrep.2022.110862. Epub 2022 May 8.

引用本文的文献

1
Disparities in anti-SARS-CoV-2 reactivity according to vaccines administered in the era of omicron in Cameroon: Lessons for future outbreak response.
PLOS Glob Public Health. 2025 Mar 19;5(3):e0004312. doi: 10.1371/journal.pgph.0004312. eCollection 2025.
2
SARS-CoV-2 shedding, infectivity, and evolution in an immunocompromised adult patient.
Rev Inst Med Trop Sao Paulo. 2024 May 13;66:e28. doi: 10.1590/S1678-9946202466028. eCollection 2024.
4
Neutralizing Activity of SARS-CoV-2 Antibodies in Patients with COVID-19 and Vaccinated Individuals.
Antibodies (Basel). 2023 Sep 25;12(4):61. doi: 10.3390/antib12040061.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验